Enliven Therapeutics, Inc. (ELVN): Shareholders' Equity

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2022-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$459.60M

As of 2025-12-31

$895.15M

As of 2026-06-30

2019-12-31 Shareholders' Equity (USD) 2025-12-31

Period ended	Shareholders' Equity	Change YoY	Source filing
2025-12-31	$459.60M	+48.3%	2026-03-03, Balance as of period end
2024-12-31	$309.85M	+26.0%	2026-03-03, Balance as of period end
2023-12-31	$245.91M	n/m	2025-03-13, Balance as of period end
2022-12-31	-$76.83M	n/c	2024-03-14, Balance as of period end
2021-12-31	$86.03M	+1.9%	2023-02-10, Balance as of period end
2020-12-31	$84.44M	n/m	2022-03-15, Balance as of period end
2019-12-31	-$48.85M	n/a	2021-03-05, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Shareholders' Equity	Change YoY
Enliven Therapeutics, Inc. (ELVN)	2025-12-31	$459.60M	+48.3%
MapLight Therapeutics, Inc. (MPLT)	2025-12-31	$458.37M	n/m
Rhythm Pharmaceuticals, Inc. (RYTM)	2025-12-31	$139.07M	+540.0%
Oruka Therapeutics, Inc. (ORKA)	2025-12-31	$471.93M	+23.5%
Vanda Pharmaceuticals Inc. (VNDA)	2025-12-31	$327.19M	-39.2%
Ardelyx, Inc. (ARDX)	2025-12-31	$166.95M	-3.7%
Biohaven Ltd. (BHVN)	2025-12-31	$52.07M	-87.7%
BridgeBio Oncology Therapeutics, Inc. (BBOT)	2025-12-31	$411.10M	n/m
Rapport Therapeutics, Inc. (RAPP)	2025-12-31	$484.65M	+58.7%

Compare ELVN, MPLT, RYTM, ORKA side by side · Screen every company in Pharmaceutical Preparations ↗